Analyst Conference Summaries |
|||||||||||||||||||||||||||||||||||||||||||||
|
Allogene Therapeutics
|
2019 | |||
Allogene Therapeutics Q4 2023 |
Allogene Therapeutics Q1 2024 |
Allogene Therapeutics Q2 2024 |
Allogene Therapeutics Q3 2024 |
Mar. 14, 2024 | May 13, 2024 | Aug. 7, 2024 | Nov. 7, 2024 |
Allogene Therapeutics (ALLO) is a clinical-stage biotechnology company specializing in second-generation CAR T therapies.
, Bought initial shares on 4/24/2024
More Analyst Conference Pages:
AGEN |
AGIO |
ALNY |
AMAT |
AMGN |
APRE |
ARWR |
BIIB |
BMY |
CLDX |
CDTX |
GILD |
GLYC |
ILMN |
IMGN |
INCY |
INKT |
INO |
IONS |
MCHP |
MRNA |
PLX |
REGN |
RNA |
SAGE |
SANA |
SYRS |
TSVT |
VSTM |
VRTX |
WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2024 William P. Meyers